Citations (30)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Cliona Grant, Fahd Rahman, Richard Piekarz, Cody Peer, Robin Frye, Robert W Robey, Erin R Gardner, William D Figg & Susan E Bates. (2010) Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors. Expert Review of Anticancer Therapy 10:7, pages 997-1008.
Read now
Read now
Walid Rasheed, Mark Bishton, Ricky W Johnstone & H Miles Prince. (2008) Histone deacetylase inhibitors in lymphoma and solid malignancies. Expert Review of Anticancer Therapy 8:3, pages 413-432.
Read now
Read now
Articles from other publishers (28)
Zhengke Wang, Yu Tina Zhao & Ting C Zhao. (2020) Histone deacetylases in modulating cardiac disease and their clinical translational and therapeutic implications. Experimental Biology and Medicine 246:2, pages 213-225.
Crossref
Crossref
Collin K. Chin & Loretta J. Nastoupil. (2020) Novel Agents Beyond Immunomodulatory Agents and Phosphoinositide-3-Kinase for Follicular Lymphoma. Hematology/Oncology Clinics of North America 34:4, pages 743-756.
Crossref
Crossref
Saikat Ghosh, Rohan Lalani, Vivek Patel, Denish Bardoliwala, Kuntal Maiti, Shubhadeep Banerjee, Subhas Bhowmick & Ambikanandan Misra. (2019) Combinatorial nanocarriers against drug resistance in hematological cancers: Opportunities and emerging strategies. Journal of Controlled Release 296, pages 114-139.
Crossref
Crossref
Chan Yoon Cheah & Nathan H. Fowler. (2018) Novel agents for relapsed and refractory follicular lymphoma. Best Practice & Research Clinical Haematology 31:1, pages 41-48.
Crossref
Crossref
Utkarsh Raj & Pritish Kumar Varadwaj. 2017. Translational Bioinformatics and Its Application. Translational Bioinformatics and Its Application
249
267
.
Veronika Borutinskaite, Justina Bauraite-Akatova & Ruta Navakauskiene. (2016) Anti-leukemic activity of DNA methyltransferase inhibitor procaine targeted on human leukaemia cells. Open Life Sciences 11:1, pages 322-330.
Crossref
Crossref
Dipanjan Bhattacharjee, Smita Shenoy & Kurady Laxminarayana Bairy. (2016) DNA Methylation and Chromatin Remodeling: The Blueprint of Cancer Epigenetics. Scientifica 2016, pages 1-11.
Crossref
Crossref
Michel Neidhart. 2016. DNA Methylation and Complex Human Disease. DNA Methylation and Complex Human Disease
419
427
.
Subrahmanya D. Vallabhapurapu, Sunil K. Noothi, Derek A. Pullum, Charles H. Lawrie, Rachel Pallapati, Veena Potluri, Christian Kuntzen, Sohaib Khan, David R. Plas, Robert Z. Orlowski, Marta Chesi, W. Michael Kuehl, P. Leif Bergsagel, Michael Karin & Sivakumar Vallabhapurapu. (2015) Transcriptional repression by the HDAC4–RelB–p52 complex regulates multiple myeloma survival and growth. Nature Communications 6:1.
Crossref
Crossref
K.V. Woan, M. Lienlaf, P. Perez-Villaroel, C. Lee, F. Cheng, T. Knox, D.M. Woods, K. Barrios, J. Powers, E. Sahakian, H.W. Wang, J. Canales, D. Marante, K.S.M. Smalley, J. Bergman, E. Seto, A. Kozikowski, J. Pinilla-Ibarz, A. Sarnaik, E. Celis, J. Weber, E.M. Sotomayor & A. Villagra. (2015) Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: Enhanced antitumor immunity and impaired cell proliferation. Molecular Oncology 9:7, pages 1447-1457.
Crossref
Crossref
Floor A.M. Duijkers, Renee X. de Menezes, Inès J. Goossens-Beumer, Dominique J.P.M. Stumpel, Pieter Admiraal, Rob Pieters, Jules P.P. Meijerink & Max M. van Noesel. (2013) Epigenetic drug combination induces genome-wide demethylation and altered gene expression in neuro-ectodermal tumor-derived cell lines. Cellular Oncology 36:5, pages 351-362.
Crossref
Crossref
Daniela Capello, Annunziata Gloghini, Gianluca Baldanzi, Maurizio Martini, Clara Deambrogi, Marco Lucioni, Daniela Piranda, Rosella Famà, Andrea Graziani, Michele Spina, Umberto Tirelli, Marco Paulli, Luigi Maria Larocca, Gianluca Gaidano, Antonino Carbone & Fabiola Sinigaglia. (2012) Alterations of negative regulators of cytokine signalling in immunodeficiency‐related non‐Hodgkin lymphoma. Hematological Oncology 31:1, pages 22-28.
Crossref
Crossref
Simon J HarrisonMark Bishton, Susan E Bates, Steven Grant, Richard L Piekarz, Ricky W Johnstone, Yun Dai, Becki Lee, Maria E Araujo & H Miles Prince. (2012)
A focus on the preclinical development and clinical status of the histone deacetylase inhibitor, romidepsin (depsipeptide, Istodax
®
)
. Epigenomics 4:5, pages 571-589.
Crossref
Crossref
Randy Jirtle, Autumn Bernal & David Skaar. 2006. Encyclopedia of Molecular Cell Biology and Molecular Medicine. Encyclopedia of Molecular Cell Biology and Molecular Medicine.
Takashi Murakami. 2011. Experimental and Applied Immunotherapy. Experimental and Applied Immunotherapy
307
322
.
Eun-Kyung Park, Eun-Hyung Jeon, In-Ho Kim & Seon-Yang Park. (2010) Recovery of Genes Epigenetically Altered by the Histone Deacetylase Inhibitor Scriptaid and Demethylating Agent 5-Azacytidine in Human Leukemia Cells. Genomics & Informatics 8:4, pages 185-193.
Crossref
Crossref
J.-H. Lee, M. L. Choy, L. Ngo, S. S. Foster & Paul A. Marks. (2010) Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair. Proceedings of the National Academy of Sciences 107:33, pages 14639-14644.
Crossref
Crossref
Junya Fujimoto, Maiying Kong, J. Jack Lee, Waun Ki Hong & Reuben Lotan. (2010) Validation of a Novel Statistical Model for Assessing the Synergy of Combined-Agent Cancer Chemoprevention. Cancer Prevention Research 3:8, pages 917-928.
Crossref
Crossref
A Villagra, E M Sotomayor & E Seto. (2009) Histone deacetylases and the immunological network: implications in cancer and inflammation. Oncogene 29:2, pages 157-173.
Crossref
Crossref
Dan Jones. 2010. Neoplastic Hematopathology. Neoplastic Hematopathology
611
626
.
Heidrun Karlic & Franz Varga. 2009. Epigenetics and Human Health. Epigenetics and Human Health
179
194
.
Andrew A. LaneBruce A. Chabner. (2009) Histone Deacetylase Inhibitors in Cancer Therapy. Journal of Clinical Oncology 27:32, pages 5459-5468.
Crossref
Crossref
Hirendra Nath BanerjeeMukesh Verma. (2009) Epigenetic mechanisms in cancer. Biomarkers in Medicine 3:4, pages 397-410.
Crossref
Crossref
H. Miles Prince, Mark J. Bishton & Simon J. Harrison. (2009) Clinical Studies of Histone Deacetylase Inhibitors. Clinical Cancer Research 15:12, pages 3958-3969.
Crossref
Crossref
H Miles PrinceMark J Bishton & Ricky W Johnstone. (2009) Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors. Future Oncology 5:5, pages 601-612.
Crossref
Crossref
A Rocca, S Minucci, G Tosti, D Croci, F Contegno, M Ballarini, F Nolè, E Munzone, A Salmaggi, A Goldhirsch, P G Pelicci & A Testori. (2009) A phase I–II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma. British Journal of Cancer 100:1, pages 28-36.
Crossref
Crossref
Min-Jung Lee, Yeong Sang Kim, Shivaani Kummar, Giuseppe Giaccone & Jane B Trepel. (2008) Histone deacetylase inhibitors in cancer therapy. Current Opinion in Oncology 20:6, pages 639-649.
Crossref
Crossref
Marshall A. Lichtman. (2008) Battling the Hematological Malignancies: The 200 Years' War. The Oncologist 13:2, pages 126-138.
Crossref
Crossref